Alex Zhavoronkov | Chief Executive Officer
Insilico Medicine, Inc

Alex Zhavoronkov, Chief Executive Officer, Insilico Medicine, Inc


Dr. Zhavoronkov specializes in the development of the next-generation artificial intelligence and Blockchain technologies for drug discovery, biomarker development and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties and launched multiple research and consumer oriented biomarker systems including the popular iPANDA system and Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative. Since 2012 he published over 80 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”.  He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is also an adjunct professor in artificial intelligence at the Buck Institute for Research on Ageing.

back to speakers

Contact us

To sponsor or exhibit contact:
Alistair Wilmot
+44 (0)207 092 1174

alistair.wilmot@terrapinn.com


To speak:
Edward Glanville
+44 (0)207 092 1042

edward.glanville@terrapinn.com